spacer
home > ict > winter 2019 > concentration-qt modelling in early phase clinical studies
PUBLICATIONS
International Clinical Trials

Concentration-QT Modelling in Early Phase Clinical Studies

Long QT syndrome is a cardiac side effect that can occur with certain pharmaceuticals. After each beat, the heart repolarises, but, with long QT syndrome, this process does not occur correctly. This can lead to a condition known as Torsadede- point arrhythmia, which can cause irregular heartbeats, fainting, and even sudden death, particularly when the patient is under stress or during exercise.

Once it was understood that drugs can cause long QT syndrome, studying cardiac repolarisation became an important part of the drug development process. Regulators now mandate assessment of whether a new drug has a tendency to prolong the QT interval as part of the clinical development process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Andreas Lindauer has been a Senior Consultant at SGS Exprimo since 2014. He studied pharmacy at the University of Bonn, Germany, subsequently completing a PhD in clinical pharmacy, focussing on PK/ PD modelling in oncology and the central nervous system.
spacer
Dr Andreas Lindauer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Trial Supply West Coast Conference 2019

Philadelphia, USA – April 24, 2019. This year’s Clinical Trial Supply West Coast Conference will see leading biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) showcasing its specialist clinical trials expertise in relation to scheduled drugs.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement